1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.

Trial Information

1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.

Patients on this study are being asked to allow the researchers to take a piece of some
normal endometrial tissue and tumor tissue. No additional endometrial tissue will be taken
for this study other than what is surgically indicated to resect the patients tumor
completely. Prior to this surgery, patients will receive one more dose of L9NC in the
outpatient clinic in the same manner as the other L9NC treatments they have received. After
the tumor has been removed, the tissue will be examined by a pathologist, who will take what
is needed to diagnose the residual disease. What is not needed for patient care will be used
for research. A piece of the tumor and some normal endometrial tissue surrounding the tumor
will be sent to the Investigational Drug Program laboratory, which is located in the Cancer
Center, to measure the amount of drug that is left in the patients tumor. The patients
tissue will be kept until all tissues are collected from all patients, which could take up
to 10 years. The tissue will not be used for any other purpose. The samples will be labeled
with the patients initials.